Bristol-Myers Squibb Company vs Burlington Stores, Inc.: Strategic Comparison

This in-depth comparison examines Bristol-Myers Squibb Company and Burlington Stores, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bristol-Myers Squibb Company on its own, evaluating Burlington Stores, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bristol-Myers Squibb Company and Burlington Stores, Inc. is widest.

On the headline numbers, Bristol-Myers Squibb Company reports annual revenue of $48.2B against $11.6B for Burlington Stores, Inc., while their respective market capitalizations stand at $127.5B and $16.8B. Both Bristol-Myers Squibb Company and Burlington Stores, Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Bristol-Myers Squibb Company: Bristol Myers Squibb (BMS) is a U.S. biopharmaceutical company headquartered in Princeton, New Jersey, and listed on the New York Stock Exchange as BMY. It develops and sells prescription medicines for cancer, blood disorders, immune diseases, heart disease and schizophrenia. Its best-known products are Eliquis, the anticoagulant it sells with Pfizer, and Opdivo, a PD-1 checkpoint inhibitor. With $48.2 billion of 2025 revenue and a market value of about $127 billion at the end of September 2026, it is one of the largest U.S. drugmakers by sales.

Burlington Stores, Inc.: Burlington, known as Burlington Coat Factory until 2013, is one of the three big U.S. off-price chains alongside TJX and Ross Stores. Shoppers come for branded women's, men's and children's clothing, shoes, accessories, baby gear in the Baby Depot department, beauty, toys and home decor, all priced below department stores. Stock changes constantly because it is bought from whatever surplus brands and retailers have, so the store works as a treasure hunt: an item on the rack this week may be gone the next. Coats remain a signature category inside a year-round assortment.

Bristol-Myers Squibb Company and Burlington Stores, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bristol-Myers Squibb Company and Burlington Stores, Inc..

Bristol-Myers Squibb Company business model: BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair. Eliquis is developed and sold with Pfizer, which shares its costs and profits. About 69 percent of 2025 revenue came from the United States, so U.S. pricing policy matters more to BMS than to most European rivals. Because every patent runs out, the model depends on replacing revenue: BMS paid $74 billion for Celgene in 2019, $13.1 billion for MyoKardia in 2020 and about $23 billion for Karuna, Mirati and RayzeBio in early 2024.

Burlington Stores, Inc. business model: Burlington makes nearly all of its money from merchandise sold in its stores. Net sales were $11.55 billion of its $11.57 billion fiscal 2025 total revenue; the remaining $17 million of other revenue comes from sources such as rental income and service fees. Its merchants buy branded goods when manufacturers or other retailers have excess stock, cancelled orders or closeouts, which lets Burlington price items below department stores. Some buys are held back as packaway inventory and released to stores later in the season or the following year. Under the Burlington 2.0 plan introduced by CEO Michael O'Sullivan, stores carry less inventory and buyers keep more money open to purchase closer to the selling season, so they can react to what is selling. The company has sold only through stores since it announced the end of its e-commerce business in March 2020, judging the small online operation unprofitable for low-priced off-price merchandise.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bristol-Myers Squibb Company stack up against those of Burlington Stores, Inc..

Bristol-Myers Squibb Company competitive advantage: BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team. Smaller biotech companies often lack that infrastructure, so they partner with or sell to a company like BMS to bring their discoveries to market.

Burlington Stores, Inc. competitive advantage: Burlington's edge is cost and flexibility. Because it does not commit to full seasonal assortments months ahead, its buyers can take excess branded inventory when it becomes available and price it below department stores. Selling only in stores, with no e-commerce since March 2020, keeps parcel shipping and online returns out of the cost base. Its real estate approach adds a further advantage: it has repeatedly taken over leases from bankrupt chains, including 62 former Bed Bath & Beyond sites in 2023 and 45 Joann sites in 2025, which gives it ready-built stores in established shopping centers.

Future prospects matter as much as current results. The growth strategies below explain how Bristol-Myers Squibb Company and Burlington Stores, Inc. each plan to expand from here.

Bristol-Myers Squibb Company growth strategy: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.

Burlington Stores, Inc. growth strategy: Burlington grows mainly by opening stores. It added 178 gross and 149 net new stores in the 12 months to August 1, 2026, and plans about 115 net openings in fiscal 2026. New stores use a smaller prototype of about 25,000 square feet instead of the very large boxes of the Coat Factory era, which lowers rent and labor per store. Many sites come from retailer bankruptcies: Burlington took on 62 Bed Bath & Beyond leases in 2023 and 45 Joann leases in 2025, and the Joann sites feed a large share of its 2026 openings. Inside existing stores, the Burlington 2.0 plan focuses on leaner inventory, faster turns and buying closer to need.

A closer look at the financial trajectory of Bristol-Myers Squibb Company and Burlington Stores, Inc. rounds out the comparison.

Bristol-Myers Squibb Company: Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion.

Burlington Stores, Inc.: Burlington's total revenue roughly doubled from $5.59 billion in fiscal 2016 to $11.57 billion in fiscal 2025. The exception was fiscal 2020, when pandemic store closures cut revenue to $5.76 billion and produced a $216.5 million net loss. Profit has since grown faster than sales: net income went from $230.1 million in fiscal 2022 to $339.6 million, $503.6 million and $610.2 million over the next three years. Heavy store investment limits free cash flow, which was about $172 million in fiscal 2025 after roughly $1.06 billion of capital spending. In the second quarter of fiscal 2026 (to August 1, 2026), total sales rose 11 percent to $2.998 billion and net income was $184 million, including a $41 million after-tax benefit from tariff refunds. The company raised its full-year adjusted EPS guidance to $11.77 to $11.97.